Nivolumab exposure in a hemodialysis patient with metastatic melanoma

xlomafota13 shared this article with you from Inoreader Nivolumab exposure in a hemodialysis patient with metastatic melanoma Via Melanoma Research - Current Issue The effect of intermittent hemodialysis (IHD) on nivolumab serum concentrations in patients with severe renal impairment is largely unknown. Here, we present a 79-year-old patient with metastatic melanoma and end-stage renal disease on IHD three times a week, treated with 480 mg nivolumab every 4 weeks. A serum trough concentration of nivolumab was determined before the start of the third cycle, and two samples were taken immediately before and after a hemodialysis session during this cycle. All nivolumab serum concentrations were within a similar range as those previously measured among patients without renal insufficiency, after a comparable duration of nivolumab treatment. Therefore, we conclude that IHD does not influence nivolumab exposure. Furthermore, nivolumab treatment was con tinued without complications and appears to be well tolerated for patients on IHD. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.